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Hormone Replacement Therapy and Intima-Media
Thickness of the Common Carotid Artery
The Rotterdam Study
I.C.D. Westendorp, MD, MSc; B.A. In’t Veld, MD, MSc; M.L. Bots, MD, PhD; J.M. Akkerhuis;
A. Hofman, MD, PhD; D.E. Grobbee, MD, PhD; J.C.M. Witteman, PhD
Background and Purpose—Observational data suggest that hormone replacement therapy (HRT) reduces morbidity and
mortality from cardiovascular disease in healthy postmenopausal women. The mechanisms underlying this protection
are not entirely clear but may include inhibition of the atherosclerotic process.
Methods—We studied the association between ever use of HRT and intima-media thickness (IMT) of the common carotid
artery in 1103 naturally menopausal women, aged 55 to 80 years, in the Rotterdam Study, a community-based cohort
study in a suburban area of Rotterdam, Netherlands. Mean and maximum IMT of the common carotid artery were
measured noninvasively with B-mode ultrasound.
Results—Ever use of HRT for $1 year was associated with a decreased mean and maximum IMT compared with never
users (mean IMT, 0.719 mm [SE 0.01] versus 0.742 mm [SE 0.004], P50.03; maximum IMT, 0.952 mm [SE 0.015]
versus 0.983 mm [SE 0.006], P50.04), after adjustment for age, smoking, educational level, systolic blood pressure, and
body mass index. No association was found for use ,1 year (mean IMT, 0.739 mm [SE 0.013] versus 0.742 mm [SE
0.004], P50.69; maximum IMT, 0.990 mm [SE 0.019] versus 0.983 mm [SE 0.006], P50.75). Additional adjustment
for diabetes, frequency of visits to healthcare facilities, or total and HDL cholesterol did not change these results.
Conclusions—The findings of this population-based study show that ever use of HRT is associated with a decreased IMT
in the common carotid artery in elderly women. (Stroke. 1999;30:2562-2567.)
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Observational data suggest that hormone replacementtherapy (HRT) reduces morbidity and mortality from
cardiovascular disease in postmenopausal women.1–3 The
mechanisms underlying this protection are not entirely clear.
Postulated mechanisms for a beneficial effect include
changes in lipid levels, hemostatic variables, and blood
viscosity; direct effects on the arterial wall; and inhibition of
the atherosclerotic process. Recently, however, a randomized
trial on the effects of HRT in women with coronary heart
disease showed no effect on the overall risk of coronary heart
disease after 4 years of treatment (the Heart and Estrogen/
Progestin Replacement Study [HERS]).4 However, an in-
creased risk of coronary heart disease events was found in the
HRT group in the first year of the trial, and the risk decreased
in subsequent years. This might be explained by an immedi-
ate prothrombotic, proarrhythmic, or proischemic effect of
treatment, which is gradually outweighed by a beneficial
effect on the progression of atherosclerosis. The results of
HERS thus do not exclude the possibility that HRT inhibits
the development of atherosclerotic disease. It is therefore
important to assess whether favorable effects of HRT on
atherosclerosis are indeed present. Data on the effects of use
of HRT on atherosclerosis are conflicting.5,6 We investigated
the association between ever use of HRT and the presence of
atherosclerosis in the carotid artery by measuring common
carotid intima-media thickness (IMT) in 1103 naturally post-
menopausal women participating in the Rotterdam Study.
Subjects and Methods
The Rotterdam Study
The Rotterdam Study is a prospective population-based follow-up
study that aims to assess the occurrence of chronic diseases in an
aging population and to clarify their determinants. The study focuses
on cardiovascular, neurogeriatric, ophthalmologic, and locomotor
diseases and has been described in more detail elsewhere.7 In brief,
all residents aged 55 and over of a defined district in Rotterdam were
invited to participate. A total of 7983 men and women (78% of those
eligible) entered the study. During the first survey, during 1990–
1993, all participants were interviewed at home by a trained research
assistant. The participants subsequently visited the study center for a
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clinical examination. A second visit to the study center took place in
1993–1994. The study was approved by the Medical Ethical Com-
mittee of Erasmus University, and informed consent was given by all
participants.
Measurements
Interview information was obtained by a trained research assistant.
Data included medical history, current medication, smoking habits,
alcohol intake, highest attained level of education, and age at last
menstruation. Menopause was defined as cessation of menses for $1
year. Height and weight were measured at the study center. Blood
pressure was measured twice with a random zero sphygmomanom-
eter with the subject in a sitting position, and the measurements were
averaged. Serum total cholesterol values were assessed by an
automated enzymatic procedure in a nonfasting blood sample. Serum
HDL cholesterol was measured after precipitation of the non-HDL
fraction with phosphotungstate-magnesium. Random and postload
serum glucose levels were assessed after an oral glucose
tolerance test.
Measurement of IMT
To measure carotid IMT, ultrasonography of the left and right
common carotid arteries was performed with a 7.5-MHz linear array
transducer (ATL UltraMark IV). On a longitudinal 2-dimensional
ultrasound image of the carotid artery, the anterior (near) and
posterior (far) walls of the carotid artery are displayed as 2 bright
white lines separated by a hypoechogenic space. The distance
between the leading edge of the first bright line of the far wall
(lumen-intima interface) and the leading edge of the second bright
line (media-adventitia interface) indicates the IMT. For the near wall,
the distance between the trailing edge of the first bright line and the
trailing edge of the second bright line at the near wall provides the
best estimate of the near wall IMT.8,9 After the ultrasound protocol,10
a careful search was performed for all interfaces of the near and far
walls of the distal common carotid artery. When an optimal longi-
tudinal image was obtained, it was frozen on the R wave of the ECG
and stored on videotape. This procedure was repeated 3 times for
both sides. The actual measurements of IMT were performed offline.
From the videotape, the frozen images were digitized and displayed
on the screen of a personal computer with the use of additional
dedicated software. This procedure has been described in detail
previously.11 With a cursor, the interfaces of the arterial segments
were marked over a length of 10 mm. The beginning of the dilatation
of the distal common carotid artery served as a reference point for the
start of the measurement. The average of the IMT of each of the 3
frozen images was calculated. For each individual, an IMT was
determined as the average of near and far wall measurements of the
left and right arteries. The readers of the ultrasound images from
videotape were unaware of the exposure status of the subject.
Reproducibility of IMT measurements was studied among 80 sub-
jects who underwent a second ultrasound scan of both carotid arteries
within 3 months of the first scan. Measurements were shown to be
highly reproducible.8 Offline the carotid artery was evaluated from
tapes for the presence (yes/no) of atherosclerotic lesions on both the
near and the far walls of the arteries. Plaques were defined as a focal
widening relative to adjacent segments, with protrusion into the
lumen composed of either only calcified deposits or a combination of
calcified and noncalcified material. The common and internal carotid
arteries and the carotid bifurcation were both evaluated online and
offline for the presence or absence of atherosclerotic lesions. In the
analyses, carotid plaque was defined as the presence of plaques at the
near or far wall at $1 site. The size of the lesions was not quantified.
A reproducibility study among 166 subjects on the assessment of
plaques in the carotid bifurcation revealed a k of 0.65 for the right
carotid artery, indicating moderate agreement.12
Assessment of Use of HRT
During the baseline interview (1990–1993), questions on ever use of
female hormones for menopausal complaints and duration of use
were asked. More information on use of female hormones was
collected by a questionnaire during the first follow-up visit to the
study center in 1993–1994, on average 2.2 years after baseline. In
this questionnaire, information on medication for menopausal com-
plaints, medication after an operation of the womb/ovaries, specific
information regarding brand and type of female hormones, duration
of use, recent use, and the use of progestins was collected.
Information from both the first and the second visits to the study
center was used for classification of subjects. At baseline, 571
women reported the use of female hormones for menopausal
complaints. Twenty-six women reported ever use of female hor-
mones in the first follow-up visit to the study center, while they had
not reported this in the baseline interview. These women were
classified as probable users. Additionally, 95 women reporting the
use of medication for menopausal complaints in the questionnaire for
the follow-up visit, but who were not sure what type of medication
this had been and who had not reported use of female hormones in
the baseline interview, were classified as possible users. Women
reporting the use of only vaginal creams or ovules were classified as
nonusers of female hormones. Thus, 692 women were classified as
ever users of female hormones at the follow-up visit. Seventy-four of
these women reported to have continued use of female hormones in
the period between the baseline and the follow-up visits. Since we
cannot be sure whether these women were current users at the time
of IMT measurement at baseline, these women were classified as
recent users.
Population for Analysis
In the Rotterdam Study, 4853 postmenopausal women participated.
Since data on use of HRT were obtained in both the first and the
second follow-up rounds, only women participating in the second
follow-up round were analyzed in this study (n53784). Excluded
were women who reported that they had reached menopause by
surgery (n5677) or radiation of the womb or ovaries (n542) and
women who were older than 80 years (n5558), since the use of HRT
in older women was rare. Furthermore, 55 women had no data on the
use of HRT. After the exclusion of women who fulfilled $1 of these
exclusion criteria, 2401 women remained for analysis. IMT was
determined in the first 1103 of these women only. Compared with
women with data on IMT, women without data were slightly
younger, had a significantly higher systolic and diastolic blood
pressure, were significantly less often past smokers. No differences
were found in other cardiovascular risk factors.
Statistical Analysis
ANCOVA was used to compare characteristics of HRT users and
nonusers, adjusted for present age. Age-adjusted linear regression
analysis was used to assess the association between risk factors and
IMT. Multivariate ANCOVA was used to assess the association
between the use of HRT and IMT. Multivariate analyses included
smoking status (current, past, and never), number of pack-years for
current and past smokers (the number of years of smoking multiplied
by the number of cigarettes smoked daily divided by 20), educational
level (in 4 categories: primary education, lower general education/
lower vocational education, intermediate vocational education, and
higher education/university), systolic blood pressure, and body mass
index (BMI). A distinction was made between short-term use (,1
year) and long-term use ($1 year) because a large group of women
had reported short-term use, and no effect on development of
atherosclerosis was expected from this. Additional analyses were
performed with adjustment for diabetes (defined as a random or
postload glucose level of .11.0 mmol/L or current use of antidia-
betic drugs), frequency of visits to healthcare facilities in the last
month, and levels of total and HDL cholesterol. To assess the effect
of past use, the analysis was repeated with the exclusion of recent
users. The analysis was repeated after exclusion of probable and
possible users. All reported P values are 2-sided. Analyses were
performed with the use of BMDP software (BMDP Statistical
Software, Inc).
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Results
At baseline, no differences were seen between ever users and
never user of HRT in age, educational level, and income
(Table 1). Long-term users had a significantly lower BMI and
were more often current smokers, although this comparison
did not reach statistical significance (P50.11). Short-term
users had a slightly higher diastolic blood pressure (P50.07)
and more pack-years of smoking (P50.06 for current and
P50.08 for past smokers) than never users. In comparison to
never users, short-term users reported significantly more
visits to the general practitioner (GP), while long-term users
reported more visits to medical specialists in the last month.
Of the 1103 women in this study, 228 reported a history of
use of HRT (20.7%). Of these, 13 did not report duration of
hormone use. Duration of use ranged from 1 month to .15
years. Seventy-nine women (36.7%) reported use for ,1
year, 68 (31.6%) for 1 to 4 years, and 68 for (31.6%) .5
years. Twenty-one women (9% of all users) reported that they
had used HRT between the first and second visits. Twenty
women (9% of all users) reported a history of use of
progestins in addition to the use of estrogens.
Mean IMT in our study group was 0.740 mm (SD 0.131)
and ranged from 0.410 to 1.518 mm. Maximum IMT was on
average 0.980 mm (SD 0.187) and ranged from 0.550 to
2.295 mm.
Table 2 shows age-adjusted associations between cardio-
vascular risk indicators and IMT. Age, systolic blood pres-
sure, total and HDL cholesterol levels, diabetes, and current
smoking were all independently and significantly associated
with IMT. The association of BMI with IMT did not reach
statistical significance (95% CI, 20.0002 to 0.0031;
P50.08).
ANCOVA showed that users of HRT had a mean age-
adjusted IMT of 0.730 mm compared with a mean IMT of
0.743 mm in nonusers (P50.13; Table 3). Stratification for
duration of use, however, showed that while use for ,1 year
was not associated with a reduction of IMT, use for $1 year
was associated with a statistically significant reduction of
TABLE 1. Age-Adjusted Baseline Characteristics of Short-Term, Long-Term, and
Never Users of Female Hormones Among Women With Natural Menopause, Aged
55 to 80 Years
Characteristic
Never Users
(n5875)
Short-Term Users
(,1 y) (n579)
Long-Term Users
($1 y) (n5136)
Age, y 67.9 (0.23) 66.5 (0.71) 67.1 (0.56)
Time since menopause, y 18.6 (0.2) 18.1 (0.5) 19.4 (0.4)
Systolic blood pressure, mm Hg 137.1 (0.7) 138.3 (2.2) 136.9 (1.9)
Diastolic blood pressure, mm Hg 71.9 (0.4) 74.2 (1.2) 72.3 (0.9)
BMI, kg/m2 27.0 (0.1) 26.7 (0.5) 26.0 (0.4)*†
Total cholesterol, mmol/L 6.96 (0.04) 6.81 (0.14) 6.98 (0.10)
HDL cholesterol, mmol/L 1.45 (0.01) 1.47 (0.04) 1.48 (0.03)
Diabetes, % 8.0 (0.9) 9.1 (0.3) 8.5 (2.3)
Current smoker, % 29.6 (1.8) 23.3 (5.9) 37.8 (4.6)
Pack-years for smokers, n 28.4 (1.4) 38.9 (5.3) 28.0 (3.0)
Former smoker, % 37.6 (1.8) 35.9 (5.9) 45.3 (4.5)
Pack-years for former smokers, n 17.6 (1.3) 25.8 (4.4) 16.9 (3.0)
Alcohol drinker, % 72 (1.6) 75 (5.2) 75 (3.9)
Visited GP in last month, % 40 (1.7) 53 (5.5)* 45 (4.2)§
Visited specialist in last month, % 19 (1.3) 26 (5.4) 26 (3.4)*†
Higher education, % highest category 20.5 (1.3) 21.3 (4.5) 26.1 (3.4)
Income, Euro per month 1192.24 (18.5) 1279.43 (61.0) 1147.24 (46.9)
Values are means or proportions (SE). Numbers do not add up to totals because of 13 missing
values for duration of hormone use.
*P,0.05 vs never users; †P,0.05, ever users vs never users.
TABLE 2. Age-Adjusted Regression Coefficients for
Association Between Cardiovascular Risk Factors and IMT
Characteristic b* 95% CI
Age (10 y) 0.087 0.077, 0.079
Systolic blood pressure (10 mm Hg) 0.012 0.008, 0.015
Diastolic blood pressure (10 mm Hg 20.005 20.012, 0.001
BMI (kg/m2) 0.0015 20.0002, 0.0031
Total cholesterol (10 mmol/L) 0.081 0.071, 0.092
HDL cholesterol (10 mmol/L) 20.241 20.433, 20.049
Diabetes (yes/no) 0.041 0.0154, 0.0657
Current smoker (yes/no) 0.0297 0.0110, 0.0485
Former smoker (yes/no) 0.0085 20.0073, 0.0242
Alcohol drinker (yes/no) 20.0043 21.0020, 0.0034
Visited GP in last month (yes/no) 0.0193 0.0051, 0.0335
Visited specialist in last month (yes/no) 20.0004 20.0177,0.0169
Higher education (highest category) 20.001 20.010,0.008
Income (per 1000 Euro) 20.005 20.019, 0.009
*Increase of IMT in millimeters per unit increase in the cardiovascular risk
factor.
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IMT. Analysis adjusted for smoking, number of pack-years
smoked, level of education, systolic blood pressure, and BMI
did not change these results. Additional adjustments for
diabetes, frequency of visits to a GP or to a medical specialist
in the last month, or total and HDL cholesterol did not change
the risk estimates. No associations were found with duration
of use in women who had used HRT for $1 year.
The numbers of recent users and users of combined
estrogen-progestin therapy were small. Comparison of mean
IMT in the 21 recent users with never users after adjustment
for age and confounders showed a decrease in IMT
(0.696 mm [SE 0.025] versus 0.741 mm [SE 0.004];
P50.08).
When we repeated the analyses excluding women report-
ing recent use of female hormones to assess the effect in past
users only, similar associations were found for past users
versus never users for mean IMT (0.719 mm [SE 0.013]
versus 0.743 mm [SE 0.004]; P50.07) and for maximum
IMT (0.940 mm [SE 0.019] versus 0.984 mm [SE 0.006];
P50.03). In addition, when we repeated the analysis after
exclusion of women who were classified as probable and
possible users (121 women), similar associations were found
for both mean and maximum IMT.
Carotid plaques were measured in 1887 of the 2401 women
eligible for this study (79%). Plaques were found present in
48% of ever users and 53% of never users after adjustment for
age and confounders (P50.15).
Discussion
We found a lower level of IMT in the common carotid artery
in women who had used HRT for $1 year compared with
never users. Use of HRT for ,1 year was not associated with
increased IMT.
Before these results are interpreted, several issues need to
be addressed. There is the possibility of selection bias in this
study of elderly women. Women had to survive until at least
age 55 years to be in our study. If a protective effect of HRT
was present, and women who had never used female hor-
mones had died of or had not responded because of athero-
sclerotic complications before the start of our study, this may
have led to an underestimation of the effect.
Several studies demonstrated that estrogen users are
healthier than never users, even before use of replacement
therapy, which supports the hypothesis that part of the
apparent benefit associated with HRT is due to preexisting
characteristics of the users.13,14 Women who take hormones
are a self-selected group and may have healthier lifestyles
with fewer risk factors than women who do not. Additionally,
compliant women who stay on estrogen represent a minority
of all women who are ever prescribed estrogen, and these
women may differ from the less compliant women. We
cannot exclude the possibility that part (or the whole) of our
findings is based on this selection bias. In this study we have
dealt with the issue of confounding in the following ways. We
stratified for duration of hormone use and found that short-
term users were similar to long-term users with respect to the
presence of several socioeconomic and risk factors, such as
income, frequency of visits to a GP or medical specialist in
the last month, alcohol consumption, and total and HDL
cholesterol levels. Among women who had used female
hormones for ,1 year, no association was present with IMT.
This diminishes but does not fully exclude the probability of
selection bias. Furthermore, we adjusted for known risk
factors. We measured the current status of risk factors, while
the exposure to hormone use had largely taken place in the
past. Socioeconomic status (level of education) may be a
major confounder but remains relatively stable over time. The
frequency of visits to healthcare facilities (possibly represent-
ing health-conscious behavior now and in the past) differed
between ever and never users of HRT, but adjustment did not
change our results. Smoking habits might have changed over
time, but misclassification of smoking habits would have
given an underestimation of the effect, because users were
more frequently smokers. BMI and alcohol intake may
undergo changes with age, and it could be that some residual
confounding has remained after adjustment. We do not expect
this to have a large effect on our results, however, because of
the relatively weak associations of these factors with IMT.
Use of HRT was assessed by interview. This might have
led, to a certain extent, to misclassification. Greendale et al15
demonstrated that a single self-report question is adequate to
ascertain ever use of postmenopausal estrogen use in women
aged ,64 years. Another study showed moderate to substan-
tial agreement between users and physicians on ever/never
use of estrogens and no differential misclassification with
disease status of the subject in women aged ,74 years.16 The
reported frequency and duration of use of HRT seemed to be
similar to those in studies in perimenopausal women in the
Netherlands, where 12% of women aged 45 and 65 years used
HRT and 50% of women discontinued use within 1 year.17–19
TABLE 3. Age-Adjusted IMT in Never Users, Short-Term Users, and Long-Term Users of HRT
Characteristic
Never Users
(n5984)
Short-Term Users (,1 y)
(n579) P *
Long-Term Users ($1 y)
(n5136) P *
Ever Users (All)
(n5228) P *
CCA IMT, mean, mm† 0.743 (0.004) 0.739 (0.013) 0.72 0.722 (0.010) 0.05 0.730 (0.008) 0.13
Adjusted full‡ 0.742 (0.004) 0.739 (0.013) 0.69 0.719 (0.010) 0.03 0.728 (0.008) 0.10
CCA IMT, maximum, mm† 0.983 (0.006) 0.990 (0.019) 0.76 0.956 (0.015) 0.09 0.970 (0.011) 0.32
Adjusted full‡ 0.983 (0.006) 0.990 (0.019) 0.75 0.952 (0.015) 0.04 0.968 (0.011) 0.23
Values in parentheses are SE. CCA indicates common carotid artery. Numbers do not add up to totals because of missing values for duration of
hormone use.
*Compared with never users.
†Adjusted for age.
‡Adjusted for age, smoking, education, systolic blood pressure, and BMI.
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According to data from the Institute of Medical Statistics
(an institution reporting yearly updates on prescriptions per
indication), the most frequently prescribed hormone therapy
in the studied period was unopposed estrogen therapy in a
dose of 0.625 mg daily. In addition to conjugated equine
estrogens, estradiol preparations were also prescribed. Pro-
gestins were added in 0.6% of prescriptions in 1970 and in
11% of prescriptions in 1986. Our observation of 9% agrees
with this statistic and with that of others.18
Increased IMT of the common carotid artery has been
shown to be associated with risk factors for atherosclero-
sis,20–22 atherosclerosis in other locations,9,12 and cardiovas-
cular disease.23,24 Thus, IMT can be used as an indicator for
generalized atherosclerosis. Ultrasonographic measurements
of IMT have been shown to be highly reproducible.8,25
The finding that HRT inhibits development of atheroscle-
rosis in the coronary arteries and aorta has been reported in
several animal studies.26–31 Studies with angiographic end
points showed a lower degree of coronary atherosclerosis in
HRT users than in nonusers.32–34 Detection bias could have
been introduced, however, if women on estrogen were se-
lected for an angiogram on the basis of less severe symptoms
in comparison with nonusers. Results from population-based
studies have been conflicting. In the Cardiovascular Health
Study, carotid IMT and stenosis in elderly women using
estrogen and progestin were similar to those of women using
estrogens alone, and both groups had a lower IMT of the
internal and common carotid arteries compared with never
users.35 Another large population-based study in women aged
,55 years (the Atherosclerosis Risk in Communities Study
[ARIC]), however, did not find an association between HRT
and IMT.5 In 2 small cross-sectional studies, a lower IMT
was found on ultrasonographic examination of the carotid
arteries36 and in the aorta and iliac arteries37 in users of
combined replacement therapy compared with nonusers.
Results from the Asymptomatic Carotid Atherosclerosis Pro-
gression Study (ACAPS) among 186 postmenopausal women
suggested that HRT may halt progression of atherosclerosis,
as measured by carotid IMT.38
Most studies focused on current users. The effect of past
use of female hormones was studied in an earlier report from
the Cardiovascular Health Study, which showed that differ-
ences in mean carotid wall thickness were greater between
current and past users than between past and never users.6
Maximum wall thickness did not differ between past and
never users. In our study the number of recent users was
small, but the exclusion of recent users from the analysis
clearly demonstrated the association in past users. Possibly,
this difference in findings can be explained by the longer
period since hormone use among women in the Cardiovas-
cular Health Study, since these women were older than the
women in our study population.
Although some studies have found an effect of duration of
use of female hormones on atherosclerosis,39–41 several large
population-based studies,6,42,43 did not find this association.
This may be explained as a reflection of unreliability of data
on duration. On the other hand, the observations of a stronger
protective effect of HRT in current than in past users, as well
as a diminishing of the protective effect after cessation of
therapy, suggest that mechanisms other than the inhibition of
atherosclerosis are also active. Our results suggest that use
of HRT for $1 year decreases the development of athero-
sclerosis, but no effect of duration of use was found.
Only 1 randomized trial on the effects of HRT on cardio-
vascular disease has been conducted (HERS). This trial in
women with diagnosed cardiovascular disease showed no
favorable effect of HRT on incident coronary heart disease
after 4.1 years of follow-up.4 This result indicates that bias in
observational studies may be larger than thought until now.
On the other hand, in the trial an increased risk for coronary
heart disease events was found in the HRT group compared
with the placebo group in the first year of the trial, but a
decreased risk was found in subsequent years. This time trend
should be interpreted with caution but might be explained as
attributable to an immediate prothrombotic, proarrhythmic, or
proischemic effect of treatment that is gradually outweighed
by a beneficial effect on the progression of atherosclerosis.
Thus, the results of the HERS trial do not exclude the
possibility that HRT might inhibit the development of ath-
erosclerosis. The aforementioned immediate effects of HRT
might be expected to be of more importance in women with
previous cardiovascular disease. Furthermore, in the HERS
trial the effects of opposed estrogen were compared with
placebo, while in our study mainly unopposed estrogen was
used. The effects of different kinds of progestins on devel-
opment of atherosclerosis remain unclear.44–46
Our results suggest that past use of HRT is associated with
a favorable atherogenic status. Further understanding of the
effects of HRT on atherogenesis can be obtained only in
randomized trials that are adequately designed to take the
distinct effects of HRT on the short and the longer term into
account.
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